Marco van der Poel led a Series B round in SQ Innovation.

Marco van der Poel led a Series B round in SQ Innovation, a Swiss biopharmaceutical company. Financial terms were not disclosed. The transaction provides the capital necessary to support the U.S. commercial launch of Lasix® ONYU (furosemide injection) 80 mg/2.67 mL for subcutaneous use following its FDA approval on October 7, 2025.